BCAT1 and prostate carcinoma: Several studies have indicated that BCAT1 overexpression is linked to multi-drug resistance, such as decreased chemosensitivity to CDDP in prostate cancer [39], and loss of BCAT1 overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer [40].